Please assess the completion status of the following clinical trial:

Trial Title: A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must meet the Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition Text Revision (DSM-IV-TR) diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD), confirmed at screening by administering the Kiddie Schedule for Affective Disorders and Schizophrenia for School Aged Children-Present and Lifetime Version.~* Patients must have an Attention-Deficit/Hyperactivity Disorder Rating Scale - IV - Parent Version: Investigator Administered and Scored, total score of less than or equal to 20 at screening and baseline.~* Patients must have a Clinical Global Impression-Attention-Deficit/Hyperactivity Disorder-Improvement score of 1 (very much better) or 2 (much better) at screening and baseline.~* Patients must have been taking either atomoxetine or osmotic-release oral system methylphenidate for the treatment of ADHD between 3 and a maximum of 15 months prior to screening.~* Patients must have been receiving the same dose of atomoxetine or osmotic-release oral system methylphenidate as monotherapy in a single daily dose during the 4 weeks prior to screening.~* For females of child-bearing potential only: Test negative for pregnancy at the time of entry based on a urine pregnancy test~* Signed informed consent document (ICD)~Exclusion Criteria:~* Patients who weigh less than 20 kilograms (kg) or more than 70 kg at study entry~* Documented history of bipolar disorder, any history of psychosis or pervasive development disorder.~* Patients with a history of any seizure disorder or patients who have taken anticonvulsant treatment for seizure control.~* Patients at serious suicidal risk.~* History of severe allergies to more than one class of medications or have had multiple adverse drug reactions.~* Patients with acute or unstable medical conditions including cardiovascular disease and hypertension.~* Patients taking excluded concomitant medications or likely to begin structured psychotherapy for ADHD.~* Patients who are currently enrolled in, or discontinued within the last 30 days from a clinical trial.~* Sexually active females who do not use a medically acceptable method of contraception.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Atomoxetine (Type: EXPERIMENTAL): Participants received 25-80 milligrams (mg) of atomoxetine orally, once daily during the run-in period for up to 7 days. The run-in period was followed by the 4-week on/off period in which participants received 25-80 mg of atomoxetine orally, once daily for 4 weeks, except for the off-days, where participants received 1 or 2 oral once daily placebo doses per week, with 6 nonconsecutive, double-blinded placebo doses in total over the 4-week on/off period. The on/off period was followed by a run-out period in which participants received 25-80 mg of atomoxetine orally, once daily for 1-5 days.
- Osmotic-release oral system methylphenidate (Type: ACTIVE_COMPARATOR): Participants received 18-54 mg of osmotic-release oral system (OROS) methylphenidate orally, once daily during the run-in period for up to 7 days. The run-in period was followed by the 4-week on/off period in which participants received 18-54 mg of OROS methylphenidate orally, once daily for 4 weeks, except for the off-days, where participants received 1 or 2 oral once daily placebo doses per week, with 6 nonconsecutive, double-blinded placebo doses in total over the 4-week on/off period. The on/off period was followed by a run-out period in which participants received 18-54 mg of OROS methylphenidate orally, once daily for 1-5 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).